Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Astria Therapeutics, Inc. - Common Stock
(NQ:
ATXS
)
13.21
+0.23 (+1.81%)
Streaming Delayed Price
Updated: 10:50 AM EST, Jan 9, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Astria Therapeutics, Inc. - Common Stock
< Previous
1
2
3
4
5
6
Next >
Halper Sadeh LLC Encourages ATXS, GDOT, UBFO Shareholders to Contact the Firm to Discuss Their Rights
December 20, 2025
Shareholders should contact the firm as there may be limited time to enforce your rights.
From
Halper Sadeh LLC
Via
GlobeNewswire
Halper Sadeh LLC Encourages ATXS, PCH, RYN Shareholders to Contact the Firm to Discuss Their Rights
November 22, 2025
Shareholders should contact the firm immediately as there may be limited time to enforce your rights
From
Halper Sadeh LLC
Via
GlobeNewswire
Astria Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Corporate Update
November 12, 2025
From
Astria Therapeutics, Inc.
Via
Business Wire
Astria Therapeutics Announces Final Positive Results from All Enrolled HAE Patients in the ALPHA-STAR Phase 1b/2 Trial of Navenibart
November 06, 2025
From
Astria Therapeutics, Inc.
Via
Business Wire
Astria Therapeutics to Present at Upcoming American College of Allergy, Asthma, and Immunology Annual Scientific Meeting
October 31, 2025
From
Astria Therapeutics, Inc.
Via
Business Wire
HALPER SADEH LLC ENCOURAGES PLYM, HOLX, ATXS, PCH SHAREHOLDERS to Contact the Firm to Discuss Their Rights
October 27, 2025
From
Halper Sadeh LLC
Via
GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Sotherly Hotels Inc. (Nasdaq – SOHO), Hologic, Inc. (Nasdaq – HOLX), Astria Therapeutics, Inc. (Nasdaq – ATXS), PotlatchDeltic Corporation (Nasdaq – PCH)
October 27, 2025
From
Brodsky & Smith LLC
Via
GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Hologic, Inc. (Nasdaq – HOLX), TrueCar, Inc. (Nasdaq – TRUE), Astria Therapeutics, Inc. (Nasdaq – ATXS), PotlatchDeltic Corporation (Nasdaq – PCH)
October 21, 2025
From
Brodsky & Smith LLC
Via
GlobeNewswire
SHAREHOLDER RIGHTS ALERT: Halper Sadeh LLC Investigates RYN, PCH, ATXS on Behalf of Shareholders
October 18, 2025
From
Halper Sadeh LLC
Via
GlobeNewswire
Astria Therapeutics Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Astria Therapeutics, Inc. - ATXS
October 17, 2025
From
Kahn Swick & Foti, LLC
Via
Business Wire
SHAREHOLDER RIGHTS ALERT: Halper Sadeh LLC Investigates TRUE, AKRO, PCH, ATXS on Behalf of Shareholders
October 16, 2025
From
Halper Sadeh LLC
Via
GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: TrueCar, Inc. (Nasdaq – TRUE), Astria Therapeutics, Inc. (Nasdaq – ATXS), PotlatchDeltic Corporation (Nasdaq – PCH), SWK Holdings Corporation (Nasdaq – SWKH)
October 16, 2025
From
Brodsky & Smith LLC
Via
GlobeNewswire
SHAREHOLDER RIGHTS ALERT: Halper Sadeh LLC Investigates ATXS and RYN on Behalf of Shareholders
October 15, 2025
From
Halper Sadeh LLC
Via
GlobeNewswire
ATXS Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Astria Therapeutics, Inc. Is Fair to Shareholders
October 14, 2025
From
Halper Sadeh LLC
Via
Business Wire
BioCryst to Acquire Astria Therapeutics, Strengthening Presence in HAE, Transforming Growth Profile
October 14, 2025
From
Astria Therapeutics, Inc.
Via
Business Wire
Astria Therapeutics to Present at Upcoming CSACI 80th Anniversary Scientific Meeting
October 09, 2025
From
Astria Therapeutics, Inc.
Via
Business Wire
Astria Therapeutics Initiates the Phase 3 ORBIT-EXPANSE Long-Term Trial of Navenibart in People with Hereditary Angioedema
October 08, 2025
From
Astria Therapeutics, Inc.
Via
Business Wire
Astria Therapeutics to Present at Upcoming 2025 HAEi Regional Conference EMEA
October 03, 2025
From
Astria Therapeutics, Inc.
Via
Business Wire
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 02, 2025
From
Astria Therapeutics, Inc.
Via
Business Wire
Astria Therapeutics Announces Positive Initial Results from the Phase 1a Healthy Subject Trial of STAR-0310 at the European Academy of Dermatology and Venereology
September 17, 2025
From
Astria Therapeutics, Inc.
Via
Business Wire
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 03, 2025
From
Astria Therapeutics, Inc.
Via
Business Wire
Astria Therapeutics to Present Initial Data from Phase 1a Trial of STAR-0310 at Upcoming European Academy of Dermatology & Venereology Congress 2025
September 03, 2025
From
Astria Therapeutics, Inc.
Via
Business Wire
Astria Therapeutics to Present at Upcoming Cantor Global Healthcare Conference
August 27, 2025
From
Astria Therapeutics, Inc.
Via
Business Wire
Astria Therapeutics Reports Second Quarter 2025 Financial Results and Provides a Corporate Update
August 12, 2025
From
Astria Therapeutics, Inc.
Via
Business Wire
Astria Therapeutics Enters into Licensing Agreement with Kaken Pharmaceutical to Develop and Commercialize Navenibart for HAE in Japan
August 06, 2025
From
Astria Therapeutics, Inc.
Via
Business Wire
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 04, 2025
From
Astria Therapeutics, Inc.
Via
Business Wire
Astria Therapeutics to Present at Upcoming 2025 US Hereditary Angioedema Association National Summit
July 07, 2025
From
Astria Therapeutics, Inc.
Via
Business Wire
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 02, 2025
From
Astria Therapeutics, Inc.
Via
Business Wire
Astria Therapeutics to Participate in Upcoming Oppenheimer Innovators in Immunology & Inflammation Summit
June 18, 2025
From
Astria Therapeutics, Inc.
Via
Business Wire
Astria Therapeutics Announces Positive Initial Results from the ALPHA-SOLAR Long-Term Open-Label Trial of Navenibart in Hereditary Angioedema Patients at the European Academy of Allergy and Clinical Immunology Annual Congress
June 13, 2025
From
Astria Therapeutics, Inc.
Via
Business Wire
< Previous
1
2
3
4
5
6
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
